490 related articles for article (PubMed ID: 34223401)
1. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.
Pawlowski C; Lenehan P; Puranik A; Agarwal V; Venkatakrishnan AJ; Niesen MJM; O'Horo JC; Virk A; Swift MD; Badley AD; Halamka J; Soundararajan V
Med; 2021 Aug; 2(8):979-992.e8. PubMed ID: 34223401
[TBL] [Abstract][Full Text] [Related]
2. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines.
McMurry R; Lenehan P; Awasthi S; Silvert E; Puranik A; Pawlowski C; Venkatakrishnan AJ; Anand P; Agarwal V; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Carlson K; Doddahonnaiah D; Metzger A; Kayal N; Berner G; Ramudu E; Carpenter C; Wagner T; Rajasekharan A; Soundararajan V
Med; 2021 Aug; 2(8):965-978.e5. PubMed ID: 34230920
[TBL] [Abstract][Full Text] [Related]
3. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
Thompson MG; Burgess JL; Naleway AL; Tyner H; Yoon SK; Meece J; Olsho LEW; Caban-Martinez AJ; Fowlkes AL; Lutrick K; Groom HC; Dunnigan K; Odean MJ; Hegmann K; Stefanski E; Edwards LJ; Schaefer-Solle N; Grant L; Ellingson K; Kuntz JL; Zunie T; Thiese MS; Ivacic L; Wesley MG; Mayo Lamberte J; Sun X; Smith ME; Phillips AL; Groover KD; Yoo YM; Gerald J; Brown RT; Herring MK; Joseph G; Beitel S; Morrill TC; Mak J; Rivers P; Poe BP; Lynch B; Zhou Y; Zhang J; Kelleher A; Li Y; Dickerson M; Hanson E; Guenther K; Tong S; Bateman A; Reisdorf E; Barnes J; Azziz-Baumgartner E; Hunt DR; Arvay ML; Kutty P; Fry AM; Gaglani M
N Engl J Med; 2021 Jul; 385(4):320-329. PubMed ID: 34192428
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
Thompson MG; Stenehjem E; Grannis S; Ball SW; Naleway AL; Ong TC; DeSilva MB; Natarajan K; Bozio CH; Lewis N; Dascomb K; Dixon BE; Birch RJ; Irving SA; Rao S; Kharbanda E; Han J; Reynolds S; Goddard K; Grisel N; Fadel WF; Levy ME; Ferdinands J; Fireman B; Arndorfer J; Valvi NR; Rowley EA; Patel P; Zerbo O; Griggs EP; Porter RM; Demarco M; Blanton L; Steffens A; Zhuang Y; Olson N; Barron M; Shifflett P; Schrag SJ; Verani JR; Fry A; Gaglani M; Azziz-Baumgartner E; Klein NP
N Engl J Med; 2021 Oct; 385(15):1355-1371. PubMed ID: 34496194
[TBL] [Abstract][Full Text] [Related]
5. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.
John BV; Deng Y; Scheinberg A; Mahmud N; Taddei TH; Kaplan D; Labrada M; Baracco G; Dahman B
JAMA Intern Med; 2021 Oct; 181(10):1306-1314. PubMed ID: 34254978
[TBL] [Abstract][Full Text] [Related]
6. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
Dickerman BA; Gerlovin H; Madenci AL; Kurgansky KE; Ferolito BR; Figueroa Muñiz MJ; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA
N Engl J Med; 2022 Jan; 386(2):105-115. PubMed ID: 34942066
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine.
Islam N; Sheils NE; Jarvis MS; Cohen K
Nat Commun; 2022 May; 13(1):2377. PubMed ID: 35501319
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence.
Puranik A; Lenehan PJ; Silvert E; Niesen MJM; Corchado-Garcia J; O'Horo JC; Virk A; Swift MD; Halamka J; Badley AD; Venkatakrishnan AJ; Soundararajan V
medRxiv; 2021 Aug; ():. PubMed ID: 34401884
[TBL] [Abstract][Full Text] [Related]
12. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.
Thompson MG; Burgess JL; Naleway AL; Tyner HL; Yoon SK; Meece J; Olsho LEW; Caban-Martinez AJ; Fowlkes A; Lutrick K; Kuntz JL; Dunnigan K; Odean MJ; Hegmann KT; Stefanski E; Edwards LJ; Schaefer-Solle N; Grant L; Ellingson K; Groom HC; Zunie T; Thiese MS; Ivacic L; Wesley MG; Lamberte JM; Sun X; Smith ME; Phillips AL; Groover KD; Yoo YM; Gerald J; Brown RT; Herring MK; Joseph G; Beitel S; Morrill TC; Mak J; Rivers P; Harris KM; Hunt DR; Arvay ML; Kutty P; Fry AM; Gaglani M
MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(13):495-500. PubMed ID: 33793460
[TBL] [Abstract][Full Text] [Related]
13. The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data.
Chodick G; Tene L; Rotem RS; Patalon T; Gazit S; Ben-Tov A; Weil C; Goldshtein I; Twig G; Cohen D; Muhsen K
Clin Infect Dis; 2022 Feb; 74(3):472-478. PubMed ID: 33999127
[TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
[TBL] [Abstract][Full Text] [Related]
15. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
16. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting.
Butt AA; Omer SB; Yan P; Shaikh OS; Mayr FB
Ann Intern Med; 2021 Oct; 174(10):1404-1408. PubMed ID: 34280332
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021.
Tenforde MW; Patel MM; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Botros M; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Naioti EA; Adams K; Lewis NM; Surie D; McMorrow ML; Self WH;
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):118-124. PubMed ID: 35085218
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
